2-amino-N,N-dimethylacetamide → HCID 59593109, compound

HRID 2262153Notes

Reaction equation

HRID 2262153 reaction equation
[NH:1]1[C:9]2[C:4](=[C:5]([C:10]3[N:11]=[C:12]([N:22]4[CH2:27][CH2:26][O:25][CH2:24][CH2:23]4)[C:13]4[S:18][C:17]([C:19](O)=[O:20])=[CH:16][C:14]=4[N:15]=3)[CH:6]=[CH:7][CH:8]=2)[CH:3]=[N:2]1.[NH2:28][CH2:29][C:30]([N:32]([CH3:34])[CH3:33])=[O:31]>>[CH3:33][N:32]([CH3:34])[C:30]([CH2:29][NH:28][C:19]([C:17]1[S:18][C:13]2[C:12]([N:22]3[CH2:23][CH2:24][O:25][CH2:26][CH2:27]3)=[N:11][C:10]([C:5]3[CH:6]=[CH:7][CH:8]=[C:9]4[C:4]=3[CH:3]=[N:2][NH:1]4)=[N:15][C:14]=2[CH:16]=1)=[O:20])=[O:31]

Participants

3

Reactant 2

HCID 49618232-amino-N,N-dimethylacetamideHCID 595931412-(1H-Indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidine-6-carboxylic acid

Product 1

HCID 59593109HCID 59593109, compound

Procedure

30 mg of 2-(1H-indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidine-6-carboxylic acid 13 was coupled to 2-amino-N,N-dimethylacetamide via General Procedure B. The product was purified via reverse phase HPLC to give 6.5 mg of 248. MS (Q1) 465.8 (M)+.

Workup

  1. customThe product was purified via reverse phase HPLC

Sources & evidence

ORD record
ord-664cb6a185564d8ab880d694f735c3e6
Source dataset
uspto-grants-2010_12
Patent number
US07846929B2

Reaction notes

Loading…